Kadence Bio
Clinical-stage biopharmaceutical company developing small-molecule therapeutics for sexual and mental health. The organization advances natural-product-inspired medicinal chemistry through preclinical pharmacology and translational studies and has progressed a lead orally administered, on‑demand candidate into Phase 1 clinical evaluation with regulatory approvals in the US and UK.
Industries
Nr. of Employees
small (1-50)
Kadence Bio
Products
Investigational oral on‑demand small‑molecule for premature ejaculation (lead asset)
A fast-acting, orally administered small-molecule candidate developed for on‑demand use to delay ejaculation; progressed into Phase 1 clinical safety and pharmacokinetic evaluation.
Investigational oral on‑demand small‑molecule for premature ejaculation (lead asset)
A fast-acting, orally administered small-molecule candidate developed for on‑demand use to delay ejaculation; progressed into Phase 1 clinical safety and pharmacokinetic evaluation.
Services
Partnership-based advancement of small-molecule candidates from discovery through first-in-human studies, including CRO-managed clinical operations and regulatory submissions.
Partnership-based advancement of small-molecule candidates from discovery through first-in-human studies, including CRO-managed clinical operations and regulatory submissions.
Expertise Areas
- Clinical trial management (first-in-human studies)
- Translational drug development
- Small-molecule medicinal chemistry
- Natural-product-inspired drug discovery
Key Technologies
- Small-molecule medicinal chemistry
- In vitro pharmacology assays (e.g., SERT, PDE4 testing)
- Preclinical in vivo models
- Oral formulation development for rapid onset
News & Updates
Article discussing men's mental health, masculinity, and connections to sexual wellbeing.
Article in the company's Sexual Wellness series addressing the orgasm gap and sexual wellbeing.
Regulatory approval of IND (FDA) and CTA (MHRA) to begin a Phase 1 safety and pharmacokinetics study in healthy male subjects.
Publication of patent applications covering synthesis and therapeutic uses of novel synthetic alkaloid compounds and a patent application specific to the candidate for ejaculatory delay.
Patent application published describing methods for delay of ejaculation using the investigational compound.
Certification as a B Corporation, indicating verified social and environmental performance and commitment to benefit-sharing and responsible practices.
Article discussing men's mental health, masculinity, and connections to sexual wellbeing.
Article in the company's Sexual Wellness series addressing the orgasm gap and sexual wellbeing.
Regulatory approval of IND (FDA) and CTA (MHRA) to begin a Phase 1 safety and pharmacokinetics study in healthy male subjects.
Publication of patent applications covering synthesis and therapeutic uses of novel synthetic alkaloid compounds and a patent application specific to the candidate for ejaculatory delay.
Patent application published describing methods for delay of ejaculation using the investigational compound.
Certification as a B Corporation, indicating verified social and environmental performance and commitment to benefit-sharing and responsible practices.